Cancer treatment

Cancer

Engineered IL-18 Variants Show Promise in Cancer Immunotherapy

Researchers at Genentech Inc. have successfully engineered interleukin-18 (IL-18), a pro-inflammatory cytokine, to enhance its stability, half-life, and manufacturability, potentially paving the way for its use in cancer immunotherapy. The engineered variant, disulfide-stabilized IL-18 Fc-fusion (dsIL-18-Fc), demonstrated improved stability and mammalian host cell production yields compared to the wild-type cytokine.